NOVEL CATHEPSIN C INHIBITORS AND THEIR USE
    3.
    发明申请
    NOVEL CATHEPSIN C INHIBITORS AND THEIR USE 审中-公开
    新型CATHEPSIN C抑制剂及其用途

    公开(公告)号:WO2006094003A1

    公开(公告)日:2006-09-08

    申请号:PCT/US2006/007162

    申请日:2006-03-01

    IPC分类号: A61K31/415 C07D231/04

    CPC分类号: C07D231/04

    摘要: The invention is directed to novel cathepsin C inhibitors and their use in the treatment of diseases mediated by the cathepsin C enzyme. Specifically, the invention is directed to compounds according to Formula (I): wherein X and n are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are cathepsin C inhibitors and can be used in the treatment of diseases mediated by the cathepsin C enzyme, such as COPD. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting cathepsin C and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

    摘要翻译: 本发明涉及新颖的组织蛋白酶C抑制剂及其在治疗由组织蛋白酶C酶介导的疾病中的用途。 具体地,本发明涉及式(I)的化合物:其中X和n定义如下,及其药学上可接受的盐。 本发明的化合物是组织蛋白酶C抑制剂,可用于治疗组织蛋白酶C酶介导的疾病,如COPD。 因此,本发明进一步涉及包含本发明化合物的药物组合物。 本发明还涉及使用本发明化合物或包含本发明化合物的药物组合物抑制组织蛋白酶C和治疗与之相关的病症的方法。

    AZAPEPTIDE ACIDS AS CELL ADHESION INHIBITORS
    5.
    发明申请
    AZAPEPTIDE ACIDS AS CELL ADHESION INHIBITORS 审中-公开
    作为细胞粘附抑制剂的十一烷酸

    公开(公告)号:WO99020272A1

    公开(公告)日:1999-04-29

    申请号:PCT/US1998/022008

    申请日:1998-10-19

    摘要: Azapeptide acids of Formula (I) are antagonists of VLA-4 and/or alpha 4 beta 7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.

    摘要翻译: 式(I)的Azapeptide酸是VLA-4和/或α4β7的拮抗剂,因此可用于抑制或预防细胞粘附和细胞粘附介导的病理。 这些化合物可以配制成药物组合物,并且适用于治疗哮喘,过敏,炎症,多发性硬化以及其它炎性和自身免疫性疾病。